JP2004520377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520377A5 JP2004520377A5 JP2002559400A JP2002559400A JP2004520377A5 JP 2004520377 A5 JP2004520377 A5 JP 2004520377A5 JP 2002559400 A JP2002559400 A JP 2002559400A JP 2002559400 A JP2002559400 A JP 2002559400A JP 2004520377 A5 JP2004520377 A5 JP 2004520377A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- phenyl
- thiazol
- trifluoromethyl
- sulfanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 perfluoro Chemical group 0.000 claims 48
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 22
- SXERGJJQSKIUIC-UHFFFAOYSA-N 2-Phenoxypropionic acid Chemical compound OC(=O)C(C)OC1=CC=CC=C1 SXERGJJQSKIUIC-UHFFFAOYSA-N 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000005275 alkylenearyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- CESIUPFUCGHEPP-UHFFFAOYSA-N 2-[2-ethyl-4-[[4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(CC)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CN2CCN(CC2)C=2C=CC(OC)=CC=2)=C1 CESIUPFUCGHEPP-UHFFFAOYSA-N 0.000 claims 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical compound CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- JXDFCRWRZXYIJF-UHFFFAOYSA-N 2-[2,5-dimethyl-4-[[4-(thiophen-3-ylmethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC2=CSC=C2)=C1C JXDFCRWRZXYIJF-UHFFFAOYSA-N 0.000 claims 1
- HTMZJWVLXDBHJQ-UHFFFAOYSA-N 2-[2-ethyl-4-[[4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)C(O)=O)C(CC)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CN2CCN(CC2)C=2C=CC(OC)=CC=2)=C1 HTMZJWVLXDBHJQ-UHFFFAOYSA-N 0.000 claims 1
- SKLCSSUNBRUUHI-UHFFFAOYSA-N 2-[2-methyl-4-[[4-(2-phenylethoxymethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)COCCC=2C=CC=CC=2)=C1 SKLCSSUNBRUUHI-UHFFFAOYSA-N 0.000 claims 1
- AMWLERATXBSGQY-UHFFFAOYSA-N 2-[2-methyl-4-[[4-(2-phenylethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CCC=2C=CC=CC=2)=C1 AMWLERATXBSGQY-UHFFFAOYSA-N 0.000 claims 1
- UPUYRFKRWFCGHL-UHFFFAOYSA-N 2-[2-methyl-4-[[4-(3-phenylpropyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CCCC=2C=CC=CC=2)=C1 UPUYRFKRWFCGHL-UHFFFAOYSA-N 0.000 claims 1
- JYYLSMURAYLXRE-UHFFFAOYSA-N 2-[2-methyl-4-[[4-(thiophen-3-ylmethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC2=CSC=C2)=C1 JYYLSMURAYLXRE-UHFFFAOYSA-N 0.000 claims 1
- DIFNTPAWTGWFIQ-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[(4-methylthiophen-2-yl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound CC1=CSC(CC2=C(SC(=N2)C=2C=CC(=CC=2)C(F)(F)F)CSC=2C=C(C)C(OCC(O)=O)=CC=2)=C1 DIFNTPAWTGWFIQ-UHFFFAOYSA-N 0.000 claims 1
- GQDOHCPKHIILRT-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[(4-phenylphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 GQDOHCPKHIILRT-UHFFFAOYSA-N 0.000 claims 1
- KRCKWKMHZJNRMT-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[(4-pyrazin-2-ylpiperazin-1-yl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CN2CCN(CC2)C=2N=CC=NC=2)=C1 KRCKWKMHZJNRMT-UHFFFAOYSA-N 0.000 claims 1
- GQSJMGIYTCKJFG-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[(4-thiophen-3-ylphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC(=CC=2)C2=CSC=C2)=C1 GQSJMGIYTCKJFG-UHFFFAOYSA-N 0.000 claims 1
- LKFODONVGVFCOU-UHFFFAOYSA-N 2-[2-methyl-4-[[4-[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid Chemical compound O1C(C)=NC(C=2C=CC(OCC3=C(SC(=N3)C=3C=CC(=CC=3)C(F)(F)F)CSC=3C=C(C)C(OCC(O)=O)=CC=3)=CC=2)=N1 LKFODONVGVFCOU-UHFFFAOYSA-N 0.000 claims 1
- NBNVSJPAESGXAG-UHFFFAOYSA-N 2-[4-[[2-(4-chlorophenyl)-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound CC=1N=C(C=2C=CC(Cl)=CC=2)SC=1CSC1=CC=C(OCC(O)=O)C(C)=C1 NBNVSJPAESGXAG-UHFFFAOYSA-N 0.000 claims 1
- FTUDUVKEOPPRET-UHFFFAOYSA-N 2-[4-[[2-(4-fluorophenyl)-4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1N1CCN(CC2=C(SC(=N2)C=2C=CC(F)=CC=2)CSC=2C=C(C)C(OC(C)(C)C(O)=O)=CC=2)CC1 FTUDUVKEOPPRET-UHFFFAOYSA-N 0.000 claims 1
- YCXWJKRXQBQMJQ-UHFFFAOYSA-N 2-[4-[[4-[(2,4-difluorophenyl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C(=CC(F)=CC=2)F)=C1 YCXWJKRXQBQMJQ-UHFFFAOYSA-N 0.000 claims 1
- QUMUTAZYSUGGAM-UHFFFAOYSA-N 2-[4-[[4-[(4-methoxyphenyl)methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1CC1=C(CSC=2C=C(C)C(OCC(O)=O)=CC=2)SC(C=2C=CC(=CC=2)C(F)(F)F)=N1 QUMUTAZYSUGGAM-UHFFFAOYSA-N 0.000 claims 1
- ZFXOVULAKVMWEM-UHFFFAOYSA-N 2-[4-[[4-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound COC1=CC=CC=C1N1CCN(CC2=C(SC(=N2)C=2C=CC(=CC=2)C(F)(F)F)CSC=2C=C(C)C(OCC(O)=O)=CC=2)CC1 ZFXOVULAKVMWEM-UHFFFAOYSA-N 0.000 claims 1
- NAVWFKOQMRRKDH-UHFFFAOYSA-N 2-[4-[[4-[[4-(3-methoxyphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound COC1=CC=CC(N2CCN(CC3=C(SC(=N3)C=3C=CC(=CC=3)C(F)(F)F)CSC=3C=C(C)C(OCC(O)=O)=CC=3)CC2)=C1 NAVWFKOQMRRKDH-UHFFFAOYSA-N 0.000 claims 1
- RJTOGUMCAKAOAU-UHFFFAOYSA-N 2-[4-[[4-[[4-(4-acetylphenyl)piperazin-1-yl]methyl]-2-(4-fluorophenyl)-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(CC2=C(SC(=N2)C=2C=CC(F)=CC=2)CSC=2C=C(C)C(OC(C)(C)C(O)=O)=CC=2)CC1 RJTOGUMCAKAOAU-UHFFFAOYSA-N 0.000 claims 1
- TWEKCBPXLSVTAH-UHFFFAOYSA-N 2-[4-[[4-[[4-(4-acetylphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-propylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(CCC)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CN2CCN(CC2)C=2C=CC(=CC=2)C(C)=O)=C1 TWEKCBPXLSVTAH-UHFFFAOYSA-N 0.000 claims 1
- GIIBXWSTEIQLJA-UHFFFAOYSA-N 2-[4-[[4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-propan-2-ylphenoxy]acetic acid Chemical compound C1=CC(OC)=CC=C1N1CCN(CC2=C(SC(=N2)C=2C=CC(=CC=2)C(F)(F)F)CSC=2C=C(C(OCC(O)=O)=CC=2)C(C)C)CC1 GIIBXWSTEIQLJA-UHFFFAOYSA-N 0.000 claims 1
- QSZGAFBRFCJZIO-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2,3-dimethylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=C(C)C(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC=CC=2)=C1 QSZGAFBRFCJZIO-UHFFFAOYSA-N 0.000 claims 1
- SCIDMMOXVKXKRB-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2,5-dimethylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC=CC=2)=C1C SCIDMMOXVKXKRB-UHFFFAOYSA-N 0.000 claims 1
- PSMIREUAPIEEPC-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-(trifluoromethyl)phenoxy]acetic acid Chemical compound C1=C(C(F)(F)F)C(OCC(=O)O)=CC=C1SCC1=C(CC=2C=CC=CC=2)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 PSMIREUAPIEEPC-UHFFFAOYSA-N 0.000 claims 1
- KFGWQADDVBAOAA-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-bromophenoxy]acetic acid Chemical compound C1=C(Br)C(OCC(=O)O)=CC=C1SCC1=C(CC=2C=CC=CC=2)N=C(C=2C=CC(=CC=2)C(F)(F)F)S1 KFGWQADDVBAOAA-UHFFFAOYSA-N 0.000 claims 1
- LTRFCDNYOSUIJC-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC=CC=2)=C1 LTRFCDNYOSUIJC-UHFFFAOYSA-N 0.000 claims 1
- WQNLZERBNDHNEG-UHFFFAOYSA-N 2-[4-[[4-benzyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]-5-chloro-2-methylphenoxy]acetic acid Chemical compound C1=C(OCC(O)=O)C(C)=CC(SCC2=C(N=C(S2)C=2C=CC(=CC=2)C(F)(F)F)CC=2C=CC=CC=2)=C1Cl WQNLZERBNDHNEG-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031103.5A GB0031103D0 (en) | 2000-12-20 | 2000-12-20 | Chemical compounds |
| PCT/US2001/051056 WO2002059098A1 (en) | 2000-12-20 | 2001-12-19 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004520377A JP2004520377A (ja) | 2004-07-08 |
| JP2004520377A5 true JP2004520377A5 (enExample) | 2005-12-22 |
| JP4234431B2 JP4234431B2 (ja) | 2009-03-04 |
Family
ID=9905490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559400A Expired - Fee Related JP4234431B2 (ja) | 2000-12-20 | 2001-12-19 | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1349843B1 (enExample) |
| JP (1) | JP4234431B2 (enExample) |
| AT (1) | ATE293611T1 (enExample) |
| DE (1) | DE60110262T2 (enExample) |
| DK (1) | DK1349843T3 (enExample) |
| ES (1) | ES2240558T3 (enExample) |
| GB (1) | GB0031103D0 (enExample) |
| PT (1) | PT1349843E (enExample) |
| WO (1) | WO2002059098A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US7105551B2 (en) | 2000-12-20 | 2006-09-12 | Smithkline Beecham Corporation | Thiazole derivatives for treating PPAR related disorders |
| GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| HRP20040098B1 (en) * | 2001-08-13 | 2012-08-31 | Janssen Pharmaceutica N.V. | 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY |
| WO2003072102A1 (en) | 2002-02-25 | 2003-09-04 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| GB0214139D0 (en) * | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| AU2003260282A1 (en) | 2002-09-05 | 2004-03-29 | Novo Nordisk A/S | Novel vinyl carboxylic acid derivatives and their therapeutical use |
| JP2005035966A (ja) * | 2002-09-06 | 2005-02-10 | Takeda Chem Ind Ltd | フランまたはチオフェン誘導体およびその医薬用途 |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| AU2003267297A1 (en) * | 2002-09-19 | 2004-04-08 | Smithkline Beecham Corporation | Process for preparing substituted phenoxy-acetic acids from phenols |
| JP4584714B2 (ja) | 2002-10-28 | 2010-11-24 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規化合物、その調製および使用 |
| WO2004037776A2 (en) | 2002-10-28 | 2004-05-06 | Novo Nordisk A/S | Novel compounds and their use as prar-modulators |
| US7129268B2 (en) | 2002-10-28 | 2006-10-31 | Novo Nordisk A/S | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives |
| US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| CN101228144A (zh) * | 2005-05-25 | 2008-07-23 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体的激活剂 |
| US7943669B2 (en) | 2005-06-30 | 2011-05-17 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
| US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| US8404726B2 (en) | 2006-04-18 | 2013-03-26 | Nippon Chemiphar Co. Ltd. | Activating agent for peroxisome proliferator activated receptor δ |
| AU2007293885A1 (en) | 2006-09-07 | 2008-03-13 | Takeda Gmbh | Combination treatment for diabetes mellitus |
| FR2910893A1 (fr) * | 2006-12-29 | 2008-07-04 | Genfit Sa | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations. |
| PL2152663T3 (pl) | 2007-06-04 | 2014-09-30 | Ben Gurion Univ Of The Negev Research And Development Authority | Związki triarylowe oraz kompozycje zawierające te związki |
| BRPI0911197A2 (pt) | 2008-04-15 | 2015-10-13 | Nippon Chemiphar Co | composto, ativador de receptor ativado pelo proliferador de peroxissoma, e, medicamento para o tratamento e /ou profilaxia de uma doença. |
| US20120094959A1 (en) | 2010-10-19 | 2012-04-19 | Bonnie Blazer-Yost | Treatment of cystic diseases |
| WO2012122368A1 (en) * | 2011-03-08 | 2012-09-13 | The Regents Of The University Of California | Deoxycytidine kinase binding compounds |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| CR20160207A (es) | 2013-11-05 | 2016-08-10 | Ben Gurion Univ Of The Negev Res And Dev Authority | Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad |
| ES3041492T3 (en) | 2019-12-18 | 2025-11-12 | Stinginn Llc | Substituted 1,2, 4-triazoles and methods of use |
| JP2023548605A (ja) | 2020-11-02 | 2023-11-17 | トレセラ コーポレーション | デオキシシチジンキナーゼ阻害剤の結晶形態およびその使用 |
| JP2024521048A (ja) * | 2021-05-19 | 2024-05-28 | スティンジン，インコーポレイテッド | Ｓｔｉｎｇシグナル伝達組成物の小分子阻害剤および使用の方法 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028052A (en) * | 1995-09-18 | 2000-02-22 | Ligand Pharmaceuticals Incorporated | Treating NIDDM with RXR agonists |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
-
2000
- 2000-12-20 GB GBGB0031103.5A patent/GB0031103D0/en not_active Ceased
-
2001
- 2001-12-19 AT AT01994514T patent/ATE293611T1/de not_active IP Right Cessation
- 2001-12-19 PT PT01994514T patent/PT1349843E/pt unknown
- 2001-12-19 DE DE60110262T patent/DE60110262T2/de not_active Expired - Lifetime
- 2001-12-19 JP JP2002559400A patent/JP4234431B2/ja not_active Expired - Fee Related
- 2001-12-19 ES ES01994514T patent/ES2240558T3/es not_active Expired - Lifetime
- 2001-12-19 DK DK01994514T patent/DK1349843T3/da active
- 2001-12-19 EP EP01994514A patent/EP1349843B1/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051056 patent/WO2002059098A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520377A5 (enExample) | ||
| JP2004534035A5 (enExample) | ||
| RU2379299C2 (ru) | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| JP2004534824A5 (enExample) | ||
| RU2004114875A (ru) | Производные дикарбоновых кислот, их получение и терапевтическое применение | |
| JP2004518702A5 (enExample) | ||
| ZA200100983B (en) | Substituted oxazoles and thiazoles derivatives as hPPAR gamma and hPPAR alpha activators. | |
| JP2004517080A5 (enExample) | ||
| JP2008513499A5 (enExample) | ||
| JP2006077019A5 (enExample) | ||
| KR920019784A (ko) | 벤조이소티아졸 및 벤조이소옥사졸-3-카복스아미드, 이의 제조방법 및 약제로서의 용도 | |
| JP2007511485A5 (enExample) | ||
| JP2005534672A5 (enExample) | ||
| JP2004517100A5 (enExample) | ||
| ZA200308352B (en) | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors. | |
| JP2007538024A5 (enExample) | ||
| JP2005529965A5 (enExample) | ||
| JP2006516251A5 (enExample) | ||
| KR970703340A (ko) | 과혈당 치료제로서의 신규한 아졸리딘디온(New azolidinediones as antihyperglycemic agents) | |
| JP2007500700A5 (enExample) | ||
| JP2006516626A5 (enExample) | ||
| RU2348616C2 (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| JP2005526732A5 (enExample) |